Evofem Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	20.24	20.18	19.36	18.22	16.84	8.24
Revenue Growth (YoY)	21.87%	4.23%	6.29%	8.20%	104.23%	1748.43%
Cost of Revenue	4.66	4.62	3.83	6.51	4.42	4.05
Gross Profit	15.58	15.57	15.53	11.71	12.42	4.19
Selling, General & Admin	16.58	17.08	20.74	26.74	71.72	138.36
Research & Development	2.1	-3.45	1.84	2.81	24.82	32.63
Amortization of Goodwill & Intangibles	0.35	0.5	0.62	-	-	-
Operating Expenses	19.03	14.13	23.21	29.55	96.55	170.99
Operating Income	-3.46	1.44	-7.68	-17.85	-84.12	-166.8
Interest Expense	-2.77	-2.64	-2.58	-2.63	-2.09	-4.73
Interest & Investment Income	0.01	0.02	0.02	0.03	0.09	0.02
Other Non Operating Income (Expenses)	-1.74	-0.36	0.4	-1.9	33.96	-33.66
EBT Excluding Unusual Items	-7.96	-1.54	-9.84	-22.34	-52.17	-205.18
Other Unusual Items	1.93	1.93	0.98	75.34	-24.49	-
Pretax Income	-6.03	0.39	-8.86	53	-76.65	-205.18
Income Tax Expense	0	0	-	0.02	0.04	0.02
Earnings From Continuing Operations	-6.03	0.39	-8.86	52.98	-76.7	-205.19
Net Income	-6.03	0.39	-8.86	52.98	-76.7	-205.19
Preferred Dividends & Other Adjustments	0.13	0.12	0.11	2.98	1.32	1.05
Net Income to Common	-6.16	0.27	-8.97	50	-78.01	-206.24
Shares Outstanding (Basic)	127	124	80	5	0	0
Shares Outstanding (Diluted)	127	6,422	80	984	0	0
Shares Change (YoY)	25.24%	7926.85%	-91.87%	211082.03%	567.40%	94.93%
EPS (Basic)	-0.05	0.00	-0.11	10.36	-167.42	-2953.95
EPS (Diluted)	-0.05	0.00	-0.11	0.05	-167.42	-2953.95
Free Cash Flow	-0.26	-2	-3.9	-8.97	-70.75	-149.61
Free Cash Flow Per Share	-0.00	-	-0.05	-0.01	-151.84	-2142.80
Gross Margin	76.96%	77.12%	80.20%	64.25%	73.78%	50.81%
Operating Margin	-17.08%	7.13%	-39.64%	-97.96%	-499.64%	-2023.30%
Profit Margin	-30.46%	1.36%	-46.30%	274.43%	-463.35%	-2501.69%
Free Cash Flow Margin	-1.27%	-9.89%	-20.14%	-49.25%	-420.21%	-1814.73%
EBITDA	-3.09	1.96	-7.03	-17.37	-83.11	-165.78
EBITDA Margin	-15.26%	9.70%	-36.29%	-95.34%	-	-
D&A For EBITDA	0.37	0.52	0.65	0.48	1.02	1.02
EBIT	-3.46	1.44	-7.68	-17.85	-84.12	-166.8
EBIT Margin	-17.08%	7.13%	-39.64%	-97.96%	-	-
Effective Tax Rate	-	0.51%	-	0.03%	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.